Pharma Major Lupin Ltd. has entered an agreement to acquire Laboratorios Grin, S.A. De C.V. (Grin), based in Mexico. The acquisition expands Lupin’s footprint into the Mexican and greater Latin American pharmaceuticals market.     Grin is a specialty pharmaceutical company engaged in the development, manufacture, and commercialization of branded ophthalmic products, with revenues of approximately $28 million in 2013, and more than 275 employees.   Ms. Vinita Gupta, chief executive officer,...